PUBLISHER: The Business Research Company | PRODUCT CODE: 1957403
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957403
Mass spectrometry imaging (MSI) is an analytical method that combines mass spectrometry with imaging to map the distribution of chemical compounds in biological or material samples. It allows visualization of molecules such as lipids, proteins, and metabolites within tissue sections. MSI provides critical molecular insights, supporting studies of disease processes, tissue architecture, and biomarker discovery. Its primary goal is to link molecular information with spatial context for a more comprehensive understanding of biological systems.
The main product types of mass spectrometry imaging include instruments, consumables, and services. Instruments are the devices used to perform MSI, analyzing the chemical composition of samples by measuring the mass-to-charge ratio of ions. Technologies employed include matrix-assisted laser desorption/ionization (MALDI), secondary ion mass spectrometry (SIMS), desorption electrospray ionization (DESI), magnetic sector mass spectrometry, time-of-flight mass spectrometry (TOFMS), and others. Applications span proteomics, metabolomics, glycomics, and more, and the technology is utilized by pharmaceutical and biotechnology companies, government and academic institutions, and other end-users.
Tariffs have affected the mass spectrometry imaging market by increasing costs of imported instruments, imaging components, and analytical consumables. These impacts are most significant in high-resolution msi instruments and advanced software-enabled systems, particularly across North America, Europe, and Asia-Pacific regions. Higher tariffs have raised capital expenditure for research institutes and pharmaceutical companies. Positively, tariffs have encouraged regional manufacturing, local service capabilities, and development of cost-optimized imaging solutions.
The mass spectrometry imaging market research report is one of a series of new reports from The Business Research Company that provides mass spectrometry imaging market statistics, including mass spectrometry imaging industry global market size, regional shares, competitors with a mass spectrometry imaging market share, detailed mass spectrometry imaging market segments, market trends and opportunities, and any further data you may need to thrive in the mass spectrometry imaging industry. This mass spectrometry imaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The mass spectrometry imaging market size has grown strongly in recent years. It will grow from $2.88 billion in 2025 to $3.14 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to advancements in mass spectrometry technologies, growth in proteomics and metabolomics research, increased funding for life sciences research, rising demand for molecular imaging tools, expansion of academic research institutions.
The mass spectrometry imaging market size is expected to see strong growth in the next few years. It will grow to $4.43 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to growth in precision medicine applications, increasing adoption of spatial biology approaches, rising pharmaceutical r&d investments, advancements in ai-enabled data interpretation, expansion of clinical research applications. Major trends in the forecast period include growing adoption of msi in biomarker discovery, increasing use of msi in cancer research, rising integration of advanced imaging and data analytics, expansion of high-resolution mass spectrometry systems, increasing demand for spatial omics technologies.
The growing demand for personalized medicine is expected to drive the growth of the mass spectrometry imaging market in the coming years. Personalized medicine tailors healthcare treatments to individual patients, taking into account their genetic makeup, environment, and lifestyle to improve treatment effectiveness. This trend is fueled by advances in genomics, which enable the development of targeted therapies based on genetic profiles, enhancing efficacy while reducing side effects. Mass spectrometry imaging supports personalized medicine by producing detailed molecular maps of tissues, aiding in the identification of disease biomarkers, and enabling the creation of therapies tailored to individual patient profiles. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, up from six approvals in 2022. Consequently, the rising demand for personalized medicine is fueling the expansion of the mass spectrometry imaging market.
Major companies in the mass spectrometry imaging (MSI) market are focusing on developing advanced technologies, such as desorption electrospray ionization (DESI), to enable more precise and detailed molecular analysis across various applications. DESI is an ionization technique that extracts ions from surfaces under ambient conditions using a charged solvent spray, allowing direct analysis of solid samples, like tissues, without extensive sample preparation or extraction. For example, in June 2023, Waters Corporation, a US-based manufacturer of analytical laboratory instruments, launched a targeted imaging mass spectrometer. The instrument enhances tissue analysis by providing improved sensitivity and speed, delivering more precise small-molecule drug analysis with higher resolution in targeted imaging. It enables faster detection, streamlines biological studies, and boosts overall accuracy and efficiency, significantly benefiting research processes. This innovation supports advanced drug development and biological research by providing detailed, high-quality molecular data.
In March 2023, Agilent Technologies Inc., a US-based manufacturer of advanced analytical, research, and diagnostic solutions, acquired e-MSion for an undisclosed amount. Through this acquisition, Agilent aims to enhance its mass spectrometry capabilities by incorporating advanced electron capture dissociation (ECD) technology, enabling researchers to obtain more detailed and accurate information on complex molecules such as proteins. e-MSion is a US-based early-stage company specializing in electron capture dissociation (ECD) technology, which allows mass spectrometers to analyze complex molecules with greater precision.
Major companies operating in the mass spectrometry imaging market are Thermo Fisher Scientific Inc., Danaher Corporation, Hitachi High-Tech Corporation, Shimadzu Corporation, Waters Corporation, Bruker Corporation, Horiba Scientific, JEOL Ltd., SCIEX, Analytik Jena AG, Standard BioTools, TOFWERK AG, Advion Inc., MassTech Inc., CovalX AG, ImaBiotech SAS, MassAnalytica LLC, Ionwerks Inc., Biognosys AG, Spectroswiss Sarl
North America was the largest region in the mass spectrometry imaging market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mass spectrometry imaging market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the mass spectrometry imaging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The mass spectrometry imaging market consists of revenues earned by entities by providing services such as quantitative analysis, molecular profiling, chemical imaging, and pathology integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The mass spectrometry imaging market includes sales of specialized detectors, mass spectrometers, testing kits, and sample preparation systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Mass Spectrometry Imaging Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses mass spectrometry imaging market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for mass spectrometry imaging ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mass spectrometry imaging market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.